Table 2.
Characterization of antiallergic eye drops evaluated in the study.
| Code | Active component (% w/v) | pH [mean (SD)] | Viscosity (mPa·s) [mean (SD)] | Osmolarity (mOsm/L) [mean (SD)] | Phosphate concentration (PO43-, ppm) | Classification according to phosphate concentration* |
|---|---|---|---|---|---|---|
| EDF 1 | Ketotifen fumarate (0.025%) | 5.31 (0.03) | 1.2 (0.00) | 245 (1.15) | < 0.6 | Without phosphates |
| EDF 2 | Azelastine hydrochloride (0.05%) | 5.69 (0.01) | 3.0 (0.00) | 278 (1.00) | 3.66 | With phosphates |
| EDF 3 | Bilastine (0.6%) | 7.32 (0.02) | 6.8 (0.12) | 294 (1.15) | < 0.3 | Phosphates-free |
| EDF 4 | Olopatadine hydrochloride (0.222%) | 7.11 (0.00) | 1.5 (0.00) | 308 (1.53) | 3,213 | With phosphates |
| EDF 5 | Azelastine hydrochloride (0.05%) | 5.90 (0.03) | 2.5 (0.00) | 282 (2.31) | < 0.6 | Without phosphates |
| EDF 6 | Olopatadine hydrochloride (0.776%) | 7.10 (0.01) | 27.7 (0.06) | 331 (4.36) | 1.8 | With phosphates |
| EDF 7 | Levocabastine hydrochloride (0.05%) | 6.94 (0.00) | 6.4 (0.06) | 1038 (3.06) | 9207 | With phosphates |
| EDF 8 | Olopatadine hydrochloride (0.1%) | 7.11 (0.00) | 1.2 (0.00) | 295 (1.53) | 3324 | With phosphates |
| EDF 9 | Ketotifen fumarate (0.025%) | 5.39 (0.01) | 1.4 (0.00) | 245 (1.15) | < 0.6 | Without phosphates |
Data are presented as the mean ± SD (standard deviation).
EDF, eye drop formulation.
*Category according to the classification described in the Material and Methods section.